Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.
Jounce Therapeutics and Ocular Therapeutix each provided investors with positive news morsels last week.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Intra-Cellular Therapies and Acadia Pharmaceuticals are worth investors' attention.
The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.
I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
Closed-end funds provide several benefits to investors over mutual funds.
South Korea is the plastic surgery capital of the world. These companies are manufacturing botox strains - but the big business is abroad, if they can crack the China and U.S. markets.